UroAlert - GU Oncology Daily

June 03, 2026

Videos

Peer-to-Peer Clinical Conversations

CORE-008 CX Early Efficacy and Tolerability Data - Aaron Berger

Aaron Berger

Aaron Berger presents CORE-008 CX arm data.

View

MEVPRO-3 Trial: Testing EZH2 Inhibition in First-Line Metastatic Hormone-Sensitive Prostate Cancer - Neeraj Agarwal

Neeraj Agarwal

Neeraj Agarwal describes MEVPRO-3, a Phase III trial randomizing 1,000 metastatic hormone-sensitive prostate cancer patients to ADT plus enzalutamide versus ADT plus enzalutamide plus mevrometostat.

View

Beyond the Abstracts

Contemporary Microhematuria Evaluation in Veterans: Cancer Detection and Resource Utilization - Beyond the Abstract

Ablative Techniques in Renal Tumours for Inoperable Patients: Step Forward in SBRT - Beyond the Abstract

Conference Coverage

AUA 2026: Machine Learning–based Prediction of Progression to Radical Nephroureterectomy After Endoscopic Management of Upper Tract Urothelial Carcinoma

AUA 2026: Long-Term Oncological Outcomes of Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-Risk Prostate Cancer: Phase 3 Randomized Controlled Trial

AUA 2026: Improved Outcomes in High-Risk Non-Muscle Invasive Bladder Cancer with Oral 5- Aminolevulinic Acid Fluorescence Cystoscopy–Assisted Transurethral Resection of Bladder Tumors

AUA 2026: Blue Light Cystoscopy Enables Earlier CIS Recognition and Can Guide Risk-Appropriate Management of High-Risk NMIBC: Real-World Outcomes from a U.S. Claims Cohort

AUA 2026: Extended Follow-up Shows Accumulating Benefit for Patients Treated with CAN-2409 + Prodrug in Combination with Standard of Care EBRT in Men with Localized Prostate Cancer – an Update from a Randomized, Placebo-Controlled Phase 3 Clinical Trial

Articles

Editor Selected Abstracts and Commentaries

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

UroAlert - GU Oncology Daily

Bladder Cancer

Renal Cancer

Prostate Cancer

Login